Patent ID: 11878056
Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 9:
10. The method for producing a highly purified AAV vector formulation according to claim 1, wherein said bona fide AAV particles comprise a transgene that encodes a gene product selected from the group consisting of thrombopoietin (TPO), interleukins, monocyte chemoattractant protein, leukemia inhibitory factor, granulocyte-macrophage colony stimulating factor, Fas ligand, tumor necrosis factors α and β, interferons α, β, and γ, stem cell factor, flk-2/flt3 ligand, IgG, IgM, IgA, IgD and IgE, chimeric immunoglobulins, humanized antibodies, single chain antibodies, T cell receptors, chimeric T cell receptors, single chain T cell receptors, class I and class II MHC molecules.